Evidence map›Paper›PMID 38847249›Full record

ArticleCurrent gene therapy2025

Single-cell and Bulk Transcriptomic Analyses Reveal a Stemness and Circadian Rhythm Disturbance-related Signature Predicting Clinical Outcome and Immunotherapy Response in Hepatocellular Carcinoma.

Xiaojing Zhu, Zixin Zhang, Jiaxing Zhang, Yanqi Xiao, Hao Wang, Mingwei Wang, Minghui Jiang, Yan Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Current gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Hepatocellular Carcinoma Around the Clock.Current oncology (Toronto, Ont.) · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaojing ZhuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Zixin ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jiaxing ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yanqi XiaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Hao WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Mingwei WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Minghui JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yan XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.

Funding

National Natural Science Foundation of China 81673036
6 · The paper itself

Abstract

aimsInvestigating the impact of stemness-related circadian rhythm disruption (SCRD) on hepatocellular carcinoma (HCC) prognosis and its potential as a predictor for immunotherapy response.

backgroundCircadian disruption has been linked to tumor progression through its effect on the stemness of cancer cells.

objectiveDevelop a novel signature for SCRD to accurately predict clinical outcomes and immune therapy response in patients with HCC.

methodsThe stemness degree of patients with HCC was assessed based on the stemness index (mRNAsi). The co-expression circadian genes significantly correlated with mRNAsi were identified and defined as stemness- and circadian-related genes (SCRGs). The SCRD scores of samples and cells were calculated based on the SCRGs. Differentially expressed genes with a prognostic value between distinct SCRD groups were identified in bulk and single-cell datasets to develop an SCRD signature.

resultsA higher SCRD score indicates a worse patient survival rate. Analysis of the tumor microenvironment revealed a significant correlation between SCRD and infiltrating immune cells. Heterogeneous expression patterns, functional states, genomic variants, and cell-cell interactions between two SCRD populations were revealed by transcriptomic, genomic, and interaction analyses. The robust SCRD signature for predicting immunotherapy response and prognosis in patients with HCC was developed and validated in multiple independent cohorts.

conclusionsIn summary, distinct tumor immune microenvironment patterns were confirmed under SCRD in bulk and single-cell transcriptomic, and SCRD signature associated with clinical outcomes and immunotherapy response was developed and validated in HCC.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorCircadian RhythmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleNeoplastic Stem CellsPrognosisTranscriptomeBiomarkers, Tumorcell-cell interactionscircadian rhythmhepatocellular carcinomaimmunohistochemical staining.immunotherapyprognosisStemness

Identifiers

PMID38847249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.